Literature DB >> 15374128

Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs.

D Garfinkel1, M Laudon, N Zisapel.   

Abstract

Benzodiazepines are widely used in the elderly population for the initiation of sleep. However, very frequently, complaints about poor sleep maintenance persist despite benzodiazepine treatment. Melatonin, a hormone produced by the pineal gland at night, is involved in the regulation of the sleep/wake cycle. Melatonin production decreases with age and can also be inhibited by benzodiazepines. We have recently reported on the association between insomnia and impaired melatonin output in the elderly. In the present study we have investigated the efficacy of melatonin replacement therapy in improving sleep in 21 elderly subjects who have been taking benzodiazepines and had low melatonin output. In a randomized, double-blind, crossover designed study the subjects were treated for three weeks with 2 mg per night of controlled-release melatonin and for 3 weeks with placebo, 2 h before desired bedtime with a 1-week washout period between treatment periods. Subjects' sleep was assessed by wrist actigraphy. Melatonin treatment significantly increased sleep efficiency and total sleep time and decreased wake after sleep onset, sleep latency, number of awakenings and fragmental index, as compared to placebo. The results of our study indicate that melatonin replacement therapy can improve sleep quality in the elderly and that the beneficial effects are augmented in the presence of benzodiazepines.

Entities:  

Year:  1997        PMID: 15374128     DOI: 10.1016/s0167-4943(96)00754-6

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  14 in total

1.  Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil.

Authors:  R Luboshitzky; Z Shen-Orr; T Shochat; P Herer; P Lavie
Journal:  J Mol Neurosci       Date:  1999-02       Impact factor: 3.444

2.  Melatonin: a non-benzodiazepine hypnotic in an elderly blind female with dementia.

Authors:  Colm Devine
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

Review 3.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

4.  An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism.

Authors:  F Giannotti; F Cortesi; A Cerquiglini; P Bernabei
Journal:  J Autism Dev Disord       Date:  2006-08

5.  The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.

Authors:  Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Glen Baker; Terry P Klassen; Sunita Vohra
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

6.  Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Authors:  Ritva Lähteenmäki; Juha Puustinen; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

7.  Melatonin, a promising role in taxane-related neuropathy.

Authors:  Z Nahleh; J Pruemer; J Lafollette; S Sweany
Journal:  Clin Med Insights Oncol       Date:  2010-04-28

Review 8.  Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

Review 9.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.